ArticleCell cycle (Georgetown, Tex.)2010
Dual association by TFAP2A during activation of the p21cip/CDKN1A promoter.
Article in Cell cycle (Georgetown, Tex.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- CREATE: cell-type-specific cis-regulatory element identification via discrete embedding.Nature communications · 2025Article
- Gene network analysis identifies dysregulated pathways in an autism spectrum disorder caused by mutations in Transcription Factor 4.Scientific reports · 2025Article
- Cocaine-Induced Changes in SpermThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2022Article
- AP-2α Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.Molecular cancer research : MCR · 2021Article
- Research of the mechanism on miRNA193 in exosomes promotes cisplatin resistance in esophageal cancer cells.PloS one · 2020Article
- Deletion of transcription factor AP-2α gene attenuates fibroblast differentiation into myofibroblast.Journal of cellular and molecular medicine · 2019Article
- Identification of human silencers by correlating cross-tissue epigenetic profiles and gene expression.Genome research · 2019Article
- The biological characteristics of transcription factors AP-2α and AP-2γ and their importance in various types of cancers.Bioscience reports · 2019Review
- Shared molecular networks in orofacial and neural tube development.Birth defects research · 2017Article
- Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.Oncotarget · 2017Article
- Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes.Endocrine-related cancer · 2016Article
- MiR-193a-5p Targets the Coding Region of AP-2α mRNA and Induces Cisplatin Resistance in Bladder Cancers.Journal of Cancer · 2016Article
- Genetics of aplasia cutis reveal novel regulators of skin morphogenesis.The Journal of investigative dermatology · 2015Review
- Article
- Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer.Oncogene · 2013Article
- Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A).Molecular and cellular biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The cyclin-dependent kinase inhibitor p21cip/CDKN1A is induced to promote growth arrest in response to a variety of stimuli in normal cells and loss of correct regulation of this gene is frequently observed in cancer. In particular, the upregulation of CDKN1A by p53 is considered to be a central mechanism of tumour suppression. Other transcription factors with tumour suppressor activity can also regulate CDKN1A, including the developmentally regulated factor, TFAP2A. Here we identify a novel AP-2 binding site within the proximal promoter of the CDKN1A gene and show this is required for optimal, p53-independent expression of p21cip/CDKN1A. We further describe a non-tumourgenic breast epithelial cell line model to study the role of endogenous TFAP2A and p53 in the control of drug-induced p21cip expression using ChIP. Maximal expression of CDKN1A requires TFAP2A which binds to two regions of the promoter: the proximal region where the AP-2 site lies and upstream near the major p53 binding site. The pattern of binding alters with time post-induction, with the proximal, p53-independent site becoming more important at later stages of p21cip induction. This pattern of promoter interaction by TFAP2A is distinct from that seen for the TFAP2C family member which represses CDKN1A expression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.